Eli Lilly to acquire Seattle-area vaccine maker for $1.5 billion - The Seattle Times
1 min readAnalysis by AlgoThesis Editorial Desk
Market Memory
What changed after the headline
The original read stays visible beside later evidence. Connections are editorial records, not ticker-only guesses.
Price since this story
Equal-weight basket · first close after publication
Price context does not establish that the story caused the move.
The story
Eli Lilly is acquiring three vaccine biotechs in a ~$20B buying spree, including a Seattle-area vaccine maker for $1.5B, as it builds an infectious disease portfolio beyond its GLP-1 franchise. The deals signal LLY is diversifying revenue streams, but the scale of simultaneous acquisitions raises integration risk and near-term cash deployment concerns.
The two-sided take
The house read
Wrong ifIf GLP-1 pipeline data or a bullish conference presentation reaffirms the core growth thesis, LLY could squeeze past $1,100+; any positive vaccine efficacy readout from an acquired asset would also invalidate the short.
Published read · research, not advice